1-3 of 3
Mitchell Smith, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Mitchell Smith, MD PhD, Opeyemi Jegede, PhD, Samir Parekh, MD, Curtis A. Hanson, MD, Peter Martin, FRCPC, MD MS, Brian G. Till, MD, Michael Crump, MD FRCPC, John P. Leonard, MD, Jonathan W. Friedberg, MD, Brad S. Kahl, MD, Thomas E. Witzig, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 751.
https://doi.org/10.1182/blood-2019-129323
Published: 2019
Journal Articles

Short-Course Therapy in Newly Diagnosed Immunodeficiency-Associated Aggressive B-Cell Lymphoma

Rami Alsharif, MD, Samah Nassereddine, MD, Esma Akin, MD, Donald Karcher, MD, Mitchell Smith, MD PhD, Eduardo Sotomayor, MD, Kieron Dunleavy, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5355.
https://doi.org/10.1182/blood-2019-124081
Published: 2019
Journal Articles

Denileukin Diftitox (ONTAK) Plus CHOP Chemotherapy in Patients with Peripheral T-Cell Lymphomas (PTCL), the CONCEPT Trial.

Francine Foss, MD, Nelida Sjak-Shie, MD, PhD, Andre Goy, MD, Eric Jacobsen, MD, Ranjana Advani, MD, Mitchell Smith, MD, PhD, Rami Komrokji, MD, Kelly Pendergrass, MD, Vanessa Bolejack, MPH, Karen Watts, Mark Acosta, PharmD
Journal: Blood
Blood (2007) 110 (11): 3449.
https://doi.org/10.1182/blood.V110.11.3449.3449
Published: 2007